Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results, Misses Estimates By $0.13 EPS

Keros Therapeutics (NASDAQ:KROS) released its quarterly earnings results on Wednesday. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13), Briefing.com reports. The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The firm’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.33) EPS.

Keros Therapeutics Trading Up 1.1 %

NASDAQ:KROS traded up $0.70 on Thursday, hitting $67.15. 267,653 shares of the stock were exchanged, compared to its average volume of 368,905. The stock has a fifty day moving average of $57.30 and a 200-day moving average of $51.99. The stock has a market cap of $2.52 billion, a PE ratio of -13.09 and a beta of 1.23. Keros Therapeutics has a fifty-two week low of $27.31 and a fifty-two week high of $73.00.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Guggenheim started coverage on Keros Therapeutics in a report on Monday, September 23rd. They set a “buy” rating and a $96.00 target price for the company. Scotiabank started coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research report on Thursday. Finally, Jefferies Financial Group initiated coverage on Keros Therapeutics in a research report on Tuesday. They set a “buy” rating on the stock. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $88.89.

Insider Activity at Keros Therapeutics

In related news, Director Carl L. Gordon sold 250,000 shares of the company’s stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares of the company’s stock, valued at $5,260,163.22. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 22.90% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.